Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Go back to Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 79.51 +0.34 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.17 | 52 Week High | $13.18 | |||
| Open | $78.99 | 52 Week Low | $6.00 | |||
| Day High | $80.40 | P/E | N/A | |||
| Day Low | $78.27 | EPS | $-1.24 | |||
| Volume | 465,073 | |||||
| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 54.33 +0.76 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.57 | 52 Week High | $3.48 | |||
| Open | $53.58 | 52 Week Low | $0.80 | |||
| Day High | $54.56 | P/E | N/A | |||
| Day Low | $53.31 | EPS | $-1.54 | |||
| Volume | 693,558 | |||||
